Entries of Restifo, Nicholas P. on the publication server

Schelker, Roland C., Fioravanti, Jessica, Mastrogiovanni, Fabio, Baldwin, Jeremy G., Rana, Nisha, Li, Peng, Chen, Ping, Vadász, Timea , Spolski, Rosanne, Heuser-Loy, Christoph, Slavkovic-Lukic, Dragana, Noronha, Pedro, Damiano, Giuseppe, Raccosta, Laura, Maggioni, Daniela, Pullugula, Sree, Lin, Jian-Xin, Oh, Jangsuk, Grandinetti, Patrick, Lecce, Mario, Hesse, Leo, Kocks, Emilia, Martín-Santos, Azucena, Gebhard, Claudia, Telford, William G., Ji, Yun, Restifo, Nicholas P., Russo, Vincenzo, Rehli, Michael , Herr, Wolfgang, Leonard, Warren J. and Gattinoni, Luca (2024) LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling. Signal Transduction and Targeted Therapy 9 (199).

Restifo, Nicholas P. and Gattinoni, Luca (2024) Synthetic soldiers: Turning T cells into immortal warriors. Journal of Experimental Medicine 221 (5), e20240258.

Mo, Fei , Yu, Zhiya, Li, Peng, Oh, Jangsuk, Spolski, Rosanne, Zhao, Liang , Glassman, Caleb R. , Yamamoto, Tori N. , Chen, Yun, Golebiowski, Filip M. , Hermans, Dalton, Majri-Morrison, Sonia, Picton, Lora K., Liao, Wei, Ren, Min, Zhuang, Xiaoxuan, Mitra, Suman, Lin, Jian-Xin, Gattinoni, Luca , Powell, Jonathan D., Restifo, Nicholas P., Garcia, K. Christopher and Leonard, Warren J. (2021) An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature 597 (7877), pp. 544-548. Fulltext not available.